Journal profile · ONCOLOGY
Translational Cancer Research
ISSN 2218-676X · eISSN 2219-6803 · AME Publishing Company · PEOPLES R CHINA
Translational Cancer Research: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.12; fully open access; APC charged, amount not published; median 70 days to acceptance (100 articles, last 24 months); 662 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Translational Cancer Research is published by AME Publishing Company and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Ferroptosis and cancer prognosis, Cancer Immunotherapy and Biomarkers and Lung Cancer Treatments and Mutations, together about 27.1% of its articles. Its main subfields are Pulmonary and Respiratory Medicine and Cancer Research. (generated from OpenAlex topic counts and CAS ranking data)
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; https://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in PubMed/PubMed Central and Web of Science [Science Citation Index Expanded (SCIE)]. Its latest impact factor (2025 citation year) is 2.1.
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Ferroptosis and cancer prognosisMedicine11.5%
- Cancer Immunotherapy and BiomarkersMedicine8.3%
- Lung Cancer Treatments and MutationsMedicine7.4%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology6%
- Lung Cancer Research StudiesMedicine4.9%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology4.5%
- Hepatocellular Carcinoma Treatment and PrognosisMedicine4.5%
- Lung Cancer Diagnosis and TreatmentMedicine3.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of SciencePMCPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.12LetPub ·
- Impact factor (publisher)
- 2.1Publisher website ·
- CiteScore 2026-06
- 2.6LetPub ·
- CiteScore (publisher) 2025
- 2.6Publisher website ·
- SJR 2026-06
- 0.52LetPub ·
- SNIP 2026-06
- 0.53LetPub ·
- h-index
- 22LetPub ·
- h-index
- 48OpenAlex ·
- i10-index
- 936OpenAlex ·
- 2-year mean citedness
- 1.42OpenAlex ·
- Self-citation rate
- 4.8%LetPub ·
- Share of gold OA articles
- 99.93%LetPub ·
Volume
- Articles per year
- 580LetPub ·
Articles by year OpenAlex count · 7,141 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 720 | 720 | 89 |
| 2025 | 662 | 662 | 807 |
| 2024 | 522 | 522 | 1,803 |
| 2023 | 332 | 332 | 1,857 |
| 2022 | 433 | 433 | 3,248 |
| 2021 | 502 | 502 | 4,765 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
70 daysMedian, submission to acceptance · P25–P75 54 days – 90 days
- Acceptance to online
- median 27 days (100 articles)
- Submission to online
- median 97 days
- Sample
- 100 articles with submission and acceptance dates (1,484 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Peer review
- Open peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Abstract
- 200–450 words
- Keywords
- 3–5
- Reference style
- Vancouver
Article types accepted22
- brief report2.7 Brief ReportLength not stated
- case reportManuscript categories Word limit Abstract Key words Main text Reference Tables and Figures Structure template Original Article No limit Structured with Backgrou…Length not stated
- case report: imdt corner2.5.1 Case Report: iMDT CornerLength not stated
- case series2.4 Case SeriesLength not stated
- clinical practice guideline2.3.1 Clinical Practice GuidelineLength not stated
- clinical practice review2.2.4 Clinical Practice ReviewLength not stated
- editorial2.10.1 EditorialLength not stated
- editorial commentary2.10.2 Editorial CommentaryLength not stated
- expert consensus2.3.2 Expert ConsensusLength not stated
- images in clinical medicine2.8 Images in Clinical MedicineLength not stated
- letter to the editor2.11 Letter to the EditorLength not stated
- literature reviewManuscript categories Word limit Abstract Key words Main text Reference Tables and Figures Structure template Original Article No limit Structured with Backgrou…Length not stated
- mini-review2.2.5 Mini-ReviewLength not stated
- narrative review (also called literature review)2.2.3 Narrative Review (Also Called Literature Review)Length not stated
- original articleManuscript categories Word limit Abstract Key words Main text Reference Tables and Figures Structure template Original Article No limit Structured with Backgrou…Length not stated
- others2.12 OthersLength not stated
- reviewManuscript categories Word limit Abstract Key words Main text Reference Tables and Figures Structure template Original Article No limit Structured with Backgrou…Length not stated
- review articleManuscript categories Word limit Abstract Key words Main text Reference Tables and Figures Structure template Original Article No limit Structured with Backgrou…Length not stated
- scoping review2.2.2 Scoping ReviewLength not stated
- study protocol2.9 Study ProtocolLength not stated
- surgical technique2.6 Surgical TechniqueLength not stated
- systematic reviewManuscript categories Word limit Abstract Key words Main text Reference Tables and Figures Structure template Original Article No limit Structured with Backgrou…Length not stated
Policy excerpts from the journal's websiteAuthorship, License & copyright, Open access, Peer review, Preprints
- Authorship 3.2 Authorship and Author contributions
3.2.1 AuthorshipAuthors should meet all four of the ICMJE’s authorship criteria listed below for authorship (1):
Source ↗Publisher website ·- License & copyright 6. COPYRIGHT AND PERMISSIONS
For specifications, please refer to: https://tcr.amegroups.org/page/about/copyright-and-permission
Source ↗Publisher website ·- Open access Open Access Statement
This journal is a peer reviewed, open access journal. All content of the journal is published under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). All articles published open access will be immediately and permanently free for all to read, download, copy and distribute as defined by the applied license.
Source ↗Publisher website ·- Peer review
Adheres to ICMJE Recommendations, COPE Code of Conduct, and WAME policy Model summary
TCR adheres to the ICMJE’s Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals (1), COPE’s Code of Conduct and Best Practice Guidelines for Journal Editors (2), and WAME’s policy (3) for generating this author instruction.
Source ↗Publisher website ·- Preprints
Non-compliant manuscripts returned for technical revision at preliminary review Model summary
To ensure a swift peer review and publication process, manuscripts that do not adhere to the following instructions will be returned to the corresponding author for technical revision at the preliminary review.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- AME Publishing Company
- Country or region
- PEOPLES R CHINA
- Language
- English
- ISSN
- 2218-676X
- Electronic ISSN
- 2219-6803
- Society / sponsor
- Society for Translational Medicine
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Translational Cancer Research
What CAS zone is Translational Cancer Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Translational Cancer Research is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Translational Cancer Research?
The latest impact factor listed by LetPub is 2.12; CiteScore 2.6, h-index 48.
How long does peer review take at Translational Cancer Research?
Based on the dates recorded on 100 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 70 days (interquartile range 54–90 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Translational Cancer Research?
According to the journal's author guidelines: Abstract: 200–450 words; Keywords: 3–5; Reference style: Vancouver. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Which databases index Translational Cancer Research?
According to LetPub and DOAJ records, Translational Cancer Research is indexed in SCIE and Scopus. The journal's website also lists Web of Science and PMC; that list has not been checked against each database.
Is Translational Cancer Research open access, and what is the APC?
Translational Cancer Research is a fully open-access journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .